Literature DB >> 10577989

Access to disease modifying treatments for rheumatoid arthritis patients.

D E Furst, F C Breedveld, G R Burmester, L Crofford, P Emery, M Feldman, J R Kalden, A Kavanaugh, E Keystone, P E Lipsky, R N Maini, L Moreland, J S Smolen, L Van De Putte, T Vischer, M Weinblatt, M Weissman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10577989      PMCID： PMC1766569          DOI： 10.1136/ard.58.2008.i129

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  14 in total

Review 1.  Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.

Authors:  M Feldmann; M J Elliott; J N Woody; R N Maini
Journal:  Adv Immunol       Date:  1997       Impact factor: 3.543

2.  NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy.

Authors:  D Kalden-Nemeth; J Grebmeier; C Antoni; B Manger; F Wolf; J R Kalden
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

Review 3.  Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis.

Authors:  M M Goldenberg
Journal:  Clin Ther       Date:  1999-01       Impact factor: 3.393

Review 4.  Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  R N Maini; M J Elliott; P J Charles; M Feldmann
Journal:  Springer Semin Immunopathol       Date:  1994

Review 5.  Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis.

Authors:  L W Moreland
Journal:  Rheum Dis Clin North Am       Date:  1998-08       Impact factor: 2.670

Review 6.  Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.

Authors:  A F Kavanaugh
Journal:  Rheum Dis Clin North Am       Date:  1998-08       Impact factor: 2.670

Review 7.  Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.

Authors:  R N Maini; M J Elliott; F M Brennan; R O Williams; C Q Chu; E Paleolog; P J Charles; P C Taylor; M Feldmann
Journal:  Immunol Rev       Date:  1995-04       Impact factor: 12.988

8.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; P Katsikis; F M Brennan; J Walker; H Bijl; J Ghrayeb
Journal:  Arthritis Rheum       Date:  1993-12

9.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

10.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

Authors:  E M Paleolog; S Young; A C Stark; R V McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1998-07
View more
  5 in total

1.  Building towards a consensus for the use of tumour necrosis factor blocking agents.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen
Journal:  Ann Rheum Dis       Date:  1999-12       Impact factor: 19.103

2.  Monoarticular septic arthritis in a patient with juvenile rheumatoid arthritis under etanercept treatment.

Authors:  Kai-Cheng Lin; Chi-Di Liang; Kuender D Yang; Hong-Ren Yu; Ho-Chang Kuo
Journal:  Rheumatol Int       Date:  2010-03-28       Impact factor: 2.631

Review 3.  Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible.

Authors:  T K Kvien; T Uhlig; I S Kristiansen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Infliximab: a review of its use in the management of rheumatoid arthritis.

Authors:  A Markham; H M Lamb
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

5.  Generation of three-dimensional pannus-like tissues in vitro from single cell suspensions of synovial fluid cells from arthritis patients.

Authors:  Samuel Solomon; Madhan Masilamani; Subhasis Mohanty; Jörg E Schwab; Eva-Maria Boneberg; Harald Illges
Journal:  Rheumatol Int       Date:  2003-06-17       Impact factor: 2.631
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.